Colitis ulcerative

• ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Not authorised
  2022-500535-36-00 5 "Moderately to severely active ulcerative colitis"
• ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Not authorised
  2022-500536-11-00 5 "Moderately to severely active ulcerative colitis"
• ABTECT-Maintenance – ABX464 Treatment Evaluation for ulcerative Colitis Therapy Not authorised
  2022-500537-84-00 5 "Moderately to severely active ulcerative colitis"
• A Randomized, Double-Blind, Placebo Controlled, Multi - Center, Phase 1b Study to Evaluate the Safety and Tolerability of LIV001 in Patients … Pending
  2024-514520-16-00 3 "mild-to-moderate active ulcerative colitis"
• Multi-center, single-arm, phase II clinical trial evaluating efficacy and in-vivo homing of adoptively transferred autologous ex-vivo expand … Pending
  2025-520628-11-00 4 "Ulcerative colitis"
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti … Pending
  2025-521038-27-00 5 "Immune system diseases"
• A study to measure mirikizumab levels in breast milk of lactating participants receiving mirikizumab therapeutically for an approved indicat … Pending
  2025-522362-78-00 6 "severely active ulcerative colitis (US) and CD (Crohn’s dise"
• A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative co … Pending
  2025-522511-42-00 4 "Crohn's disease"
• A Phase 2a Study of the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Co … Recruiting
  2024-520201-39-00 4 2025-08-28 "Moderately to Severely Active Ulcerative Colitis"
• A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participant … Recruiting
  2023-505678-14-00 4 2024-08-19 "Ulcerative Colitis"
• A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with a … Recruiting
  2023-509606-30-00 5 2024-07-24 "Ulcerative colitis"
• Ulcerative Colitis: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects with Moderately to Severely Active Ulcerati … Recruiting
  2022-501788-41-00 5 2023-11-14 "Ulcerative Colitis"
• GRT-1C102: A randomized, double-blind, placebo-controlled dose escalation study to evaluate the safety, tolerability, and pharmacokinetics/p … Recruiting
  2025-524328-24-00 3 2026-05-06 "Ulcerative colitis"
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis Recruiting
  2025-521035-37-00 5 2026-03-02 "Immune system diseases"
• A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn’s Disease (CD) Recruiting
  2024-518914-18-00 4 2025-08-27 "Moderate to Severely Active Ulcerative Colitis & Moderate to"
• SIMBA Recruiting
  2024-514740-82-00 6 2025-07-16 "Inflammatory Bowel Disease"
• A study to investigate efficacy and safety of SAR441566 in patients with ulcerative colitis Recruiting
  2025-520705-12-00 4 2025-06-24 "Colitis Ulcerative"
• A Study to Test the Activity and Safety of Vixarelimab in Patients with Moderate to Severe Active Ulcerative Colitis Recruiting
  2024-516287-29-00 3 2025-02-26 "Moderate to Severe Active Ulcerative Colitis (UC)"
• A trial to evaluate the efficacy and safety of oral controlled-ileocolonic-release nicotinamide (CICR-NAM) in patients with mild to moderate … Recruiting
  2024-510807-13-00 10 2024-09-12 "ulcerative colitis"
• A randomized, double-blind, placebo-controlled, single and multiple-dose-escalation, phase 1 study in healthy volunteers and patients with u … Recruiting
  2023-507547-11-00 1 2024-02-09 "Ulcerative colitis"
• An open-label randomized trial COmparing staNdard of care versus Treat to target with telemonitoRing and patient education in patients with … Recruiting
  2023-507256-76-00 6 2020-01-14 "Ulcerative colitis"
• Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (risankizumab biosimilar), with EU-approved Skyrizi®, and US … Recruitment ended
  2025-522345-21-00 1 2025-11-11 "Active psoriatic arthritis"
• A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in … Recruitment ended
  2023-506769-67-00 4 2024-09-04 "Moderate to Severely Active Ulcerative Colitis"
• Dose-finding study of SAR443122 in adult participants with ulcerative colitis Recruitment ended
  2022-500290-14-01 4 2023-05-11

Showing 1–24 of 47 trials